Sign up

Tang Capital Management LLC

$2.2B assets · 41 holdings · Q2 2026 · Filed 14 AUG 2026

About Tang Capital Management LLC’s 13F portfolio

Tang Capital Management LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Tang Capital Management LLC reported $2.2B across 41 US-listed positions (). Its largest position is AURINIA PHARMACEUTICALS INC (AUPH) at 10% of the reported book, and its ten biggest holdings make up 63% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$2.2B
Assets (13F)
#1,400
of 8,839 by size
41
Holdings
63%
Top-10 weight
12
Buys
20
Sells
Top holdings · Q2 2026
41 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: AUPH
AURINIA PHARMACEUTICALS INC
—
—
10%
13.0M$221.4M
2
NASDAQ: SYRE
SPYRE THERAPEUTICS INC
—
—
7.6%
1.9M$168.0M
3
NASDAQ: MIRM
MIRUM PHARMACEUTICALS INC
—
—
6.6%
1.2M$144.7M
4
NASDAQ: KNSA
KINIKSA PHARMACEUTICALS INTL
—
—
6.6%
2.3M$144.5M
5
NASDAQ: CELC
CELCUITY INC
—
—
6.2%
1.3M$137.5M
6
NASDAQ: CORT
CORCEPT THERAPEUTICS INC
—
—
5.9%
1.5M$130.4M
7
NASDAQ: PTCT
PTC THERAPEUTICS INC
—
—
5.6%
1.5M$122.4M
8
NASDAQ: GLPG
LAKEFRONT BIOTHERAPEUTICS NV
—
—
5.2%
3.8M$113.5M
9
NASDAQ: CAPR
CAPRICOR THERAPEUTICS INC
—
—
4.5%
4.1M$98.7M
10
NASDAQ: TARS
TARSUS PHARMACEUTICALS INC
—
—
4.5%
1.6M$98.7M
11
NYSE Arca: SPY
STATE STR SPDR S&P 500 ETF T
—
—
4.2%
123K$91.9M
12
NASDAQ: ANAB
ANAPTYSBIO INC
—
—
4.1%
1.3M$89.8M
13
NASDAQ: IMCR
IMMUNOCORE HLDGS PLC
—
—
3.8%
2.6M$84.1M
14
NASDAQ: CMPS
COMPASS PATHWAYS PLC
—
—
3.2%
5.0M$70.8M
15
NASDAQ: ANIP
ANI PHARMACEUTICALS INC
—
—
2.7%
708K$58.6M
16
NASDAQ: BNTX
BIONTECH SE
—
—
2.0%
470K$43.7M
17
NASDAQ: CMPX
COMPASS THERAPEUTICS INC
—
—
1.8%
18.0M$39.4M
18
NASDAQ: PGEN
PRECIGEN INC
—
—
1.7%
6.4M$36.6M
19
NASDAQ: VRDN
VIRIDIAN THERAPEUTICS INC
—
—
1.5%
1.8M$32.9M
20
NASDAQ: NVCT
NUVECTIS PHARMA INC
—
—
1.3%
1.6M$28.5M
21
NASDAQ: DNTH
DIANTHUS THERAPEUTICS INC
—
—
1.2%
265K$25.8M
22
NASDAQ: FULC
FULCRUM THERAPEUTICS INC
—
—
1.1%
6.5M$23.9M
23
NASDAQ: AVIR
ATEA PHARMACEUTICALS INC
—
—
1.0%
4.8M$22.4M
24
NASDAQ: CBIO
CRESCENT BIOPHARMA INC.
—
—
0.9%
1.2M$20.9M
25
NASDAQ: NNDM
NANO DIMENSION LTD
—
—
0.9%
14.3M$20.7M

Showing 1–25 of 41 positions on this page reported in this 13F.

Sector allocation
  • Healthcare95%
  • Technology0.9%
Recent activity · vs 2026-03-31
Bought12
  • AddedAUPHAURINIA PHARMACEUTICALS INC+6.7%$221.4M
  • AddedCELCCELCUITY INC+25.2%$137.5M
  • AddedCAPRCAPRICOR THERAPEUTICS INC+20.6%$98.7M
  • AddedTARSTARSUS PHARMACEUTICALS INC+31.9%$98.7M
  • AddedCMPSCOMPASS PATHWAYS PLC+24.9%$70.8M
  • AddedCMPXCOMPASS THERAPEUTICS INC+7.1%$39.4M
  • NewNVCTNUVECTIS PHARMA INC—$28.5M
  • NewFULCFULCRUM THERAPEUTICS INC—$23.9M
  • NewNNDMNANO DIMENSION LTD—$20.7M
  • AddedNUVBNUVATION BIO INC+4.8%$18.7M
Sold20
  • ReducedSPYSTATE STR SPDR S&P 500 ETF T−26.8%$91.9M
  • ReducedINSMINSMED INC−61.5%$10.7M
  • ReducedSTOKSTOKE THERAPEUTICS INC−40.0%$9.8M
  • ReducedPLRXPLIANT THERAPEUTICS INC−0.0%$7.0M
  • ReducedMRNAMODERNA INC−50.0%$3.5M
  • SoldNMRANEUMORA THERAPEUTICS INC.−100%—
  • SoldJANXJANUX THERAPEUTICS INC−100%—
  • SoldKALVKALVISTA PHARMACEUTICALS INC−100%—
  • SoldABEOABEONA THERAPEUTICS INC−100%—
  • SoldEOLSEVOLUS INC−100%—
5%+ Beneficial Ownership Stakes · 5 activist (13D) · 17 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
—
ITeos Therapeutics, Inc.
13D100.0%!10KFiled 03 SEP 2025
2
—
Cargo Therapeutics, Inc.
13D100.0%!10KFiled 21 AUG 2025
3
—
Allakos Inc.
13D100.0%!10KFiled 19 MAY 2025
4
BOLD
Boundless Bio, Inc.
13G12.5%2.8MFiled 16 NOV 2026
5
FULC
Fulcrum Therapeutics, Inc.
13G10.4%6.9MFiled 15 JUL 2026
6
CMPX
Compass Therapeutics, Inc.
13G10.0%17.2MFiled 14 NOV 2025
7
PMVP
PMV Pharmaceuticals, Inc.
13G10.0% · 2 classes7.6MFiled 16 NOV 2026
8
KALV
KalVista Pharmaceuticals, Inc.
13G9.9%4.9MFiled 15 MAY 2025
9
EYPT
EyePoint, Inc.
13G9.6%8.3MFiled 27 OCT 2026
10
PLRX
Pliant Therapeutics, Inc.
13D9.6%5.9MFiled 10 MAR 2025
11
AUPH
Aurinia Pharmaceuticals Inc.
13D9.2% · 2 classes12.2MFiled 03 MAR 2026
12
NNDM
Nano Dimension Ltd.
13G9.1%19.2MFiled 21 AUG 2026
13
GLPG
Galapagos NV
13G8.4%5.6MFiled 29 OCT 2025
14
DERM
Journey Medical Corporation
13G8.0%1.9MFiled 15 MAY 2025
15
PRTC
PureTech Health plc
13G7.3%17.9MFiled 16 NOV 2026
16
CAPR
Capricor Therapeutics, Inc.
13G6.6%3.4MFiled 26 JAN 2026
17
AVIR
Atea Pharmaceuticals, Inc.
13G6.0%4.8MFiled 06 OCT 2026
18
SKYE
Skye Bioscience, Inc.
13G6.0%264KFiled 14 OCT 2026
19
ARDX
Ardelyx, Inc.
13G5.7%14.3MFiled 17 NOV 2026
20
IMCR
Immunocore Holdings plc
13G5.2%2.6MFiled 24 OCT 2025
21
KNSA
Kiniksa Pharmaceuticals International, plc
13G5.2%2.2MFiled 04 APR 2025
22
CBIO
Crescent Biopharma, Inc.
13G5.0%700KFiled 09 OCT 2025

Showing all 22 disclosed stakes. 8 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Tang Capital Management LLC’s 13F portfolio

Tang Capital Management LLC’s $2.2B 13F book is spread across 41 reported positions and is highly concentrated — its ten largest positions alone are 63% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are AUPH, SYRE, MIRM, KNSA and CELC, led by AURINIA PHARMACEUTICALS INC (AUPH) at 10% of the portfolio. The heaviest sector exposure is Healthcare (95%), then Technology (1%).

What Tang Capital Management LLC changed last quarter

Between 2026-03-31 and Q2 2026, Tang Capital Management LLC was a net seller: it opened 5 new positions and added to 7 more, while trimming 5 and closing 15 outright. Against a 41-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was AURINIA PHARMACEUTICALS INC (AUPH), and its biggest reduction was STATE STR SPDR S&P 500 ETF T (SPY).

What a 13F does and doesn’t reveal

A 13F captures only Tang Capital Management LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Tang Capital Management LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Tang Capital Management LLC's profile on this page is built directly from those filings.

How current is the 13F data on Tang Capital Management LLC's page?

It reflects Tang Capital Management LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Tang Capital Management LLC files its next quarterly report, this page refreshes automatically.

Can I see Tang Capital Management LLC's complete list of holdings?

This page highlights Tang Capital Management LLC's largest positions rather than all 41 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Tang Capital Management LLC's filings.

Does a 13F show everything Tang Capital Management LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Tang Capital Management LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Tang Capital Management LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.